Jazz Swings on Favorable Court Ruling
This article was originally published in The Pink Sheet Daily
Executive Summary
An initial court ruling signals that the specialty pharma may be on the right track to staving off a generic version of narcolepsy drug Xyrem.
You may also be interested in...
Not Jazzed About Xyrem REMS, Irish Company Begins Dispute Resolution
Jazz will begin dispute resolution with FDA regarding the risk evaluation and mitigation strategy for its best-selling wakefulness drug.
Jazz And Concert In Tune On Xyrem
The two biotech companies have teamed up to create a follow-on product to Jazz’s narcolepsy drug, a collaboration that could add to the patent-life of Xyrem and be financially beneficial for both companies.
Jazz Cools On Women’s Health, Sells Unit To Meda
The sale of an asset portfolio that includes Elsetrin for hot flashes could give Jazz the financial flexibility for another product acquisition.